Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878888 · ClinicalTrials.gov registry record · Phase 4
Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control
A Phase 4 study, sponsored by St. Luke's Hospital, Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT03878888: Completed Phase 4 study, sponsored by St. Luke's Hospital, Pennsylvania.
NCT03878888 is a Phase 4 study that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03878888, a Phase 4 study, has completed, sponsored by St. Luke's Hospital, Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay
Primary Outcome
will review opioid/narcotic use in patient's chart
Interventions
- DRUG Exparel 266 MG Per 20 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 4 |
What the finished NCT03878888 record still lists
NCT03878888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Exparel 266 MG Per 20 ML Injection is the first listed.
NCT03878888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03878888 about?
NCT03878888 is a clinical study titled "Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control". To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospi...
What is the current status of trial NCT03878888?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2019-01-15. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT03878888?
The interventions under investigation include: Exparel 266 MG Per 20 ML Injection (DRUG).
Who is sponsoring clinical trial NCT03878888?
This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03878888's enrollment target sits among peer trials
52 1233rd of 2000 higher than 752 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI